Studies on the Molecular Mechanism of Hypolipidemic Action of 3-Hydroxy-3-Methylglutaric Acid by Iqrar, Shabana
STUDIES ON THE MOLECULAR MECHANISM OF HYPOLIPIDEMIC ACTION OF 
3-HYDR0XY-3-METHYLGLUTARIC ACID. 
DISSERTATION SUBMITTED 
IN PARTIAL FULFILMENT FOR THE DEGREE OF 
MASTER OF PHILOSOPHY 
IN 
BIOCHEMISTRY 
BY 
SHABANA IQRAR 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF LIFE SCIENCES 
ALIGARH MUSLIM UNIVERSITY 
ALIG'ARH 
1987 
DEDICATED 
TO 
MY PARENTS 
t M fn Co-^nn 
nrc^ 
Z7 APR \9W 
CHEC>n:D-200^ 
DS1076 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF LIFE SCIENCES 
ALIGARH MUSLIM UNIVERSITY ALIGARH (INDIA) 
CERTIFICATE 
I certi-fy that the work presented in this dissertation 
has been carried out by Miss SHABANA IQF<AR under my supervision 
and i s s u i t a b 1 e -f o r t h e a w a r d o t M. P h i 1 . d e g r e e i n B i o c: h e en i <s 11 • y, 
Uate: July V, 1987 
( A.M. Siddiqi ) 
P r o f e s s o r o t B i t j c hi e rn i s t i- • 
ACKNOWLEDGEMENTS 
I wish to offer my profound gratitude to Prof. A.M. Siddiqi, 
Dean, Faculty of Life Sciences for his excellent guidance, constant 
support/Constructive criticism and generous availability of re^rch 
facilities throughout the course of this study. 
I am highly grateful to Dr. M.Saleemuddin for his presistent 
interest and valuable suggestions. 
My sincere thanks are also due to Drs. S.M. Hadi, Masood 
Ahmad," Mrs. B. Banc and Mrs. N. Banu for encouragement and helpful 
discussions at all levels. 
I am also thankful to all my friends and colleagues, especi-
ally Zehra Rehana, for their amicable help and cooperation. 
University Grants Cohimission is also acknowledged for finan-
cial assistance. 
Mr. Sabir Ali deserves a word of praise for the expert 
typing of this manuscript. 
( Shabana Iqrar ) 
CONTENTS 
PAGE 
LIST OF ABBREVIATIONS 
INTRODUCTION 1 
A. ETIOLOGY 2 
B. ATHEROSCLEROSIS AND LIPOPROTEINS 4 
C. HYPOLIPEDEMIC COMPOUNDS 12 
D. GENESIS OF THE PRESENT WORK 22 
EXPERIMENTAL 
A. MATERIALS 26 
B. METHODS 27 
C. TREATMENT OF DATA 36 
RESULTS AND DISCUSSION 37 
FUTURE PLAN 48 
BIBLIOPGRAPHY 49 
LIST OF ABBREVIATIONS 
ANSA 
apo-
CHD 
CPIB 
CPK 
FFA 
GOT 
GPT 
HDL 
HMG 
HMG CoA 
h 
IDL 
IHD 
i.p. 
LCAT 
LDH 
LDL 
rain 
TG 
VLDL 
Amino naphthosulphonic acid 
Apoliproproteins 
Coronary heart disease 
Ethyl p-chlorophenoxyisobutyrate 
Creatine phosphokinase 
Free Fatty acids 
Glutamate-oxaloacetate transaminase 
Glutamate-pyruvate transaminase 
High density lipoproteins 
3-hydroxy-3-methyl glutaric acid 
3-hydroxy-3-methylglutaryl coenzyme A 
Hour (s) 
Intermediate density lipoprotein 
Ischaemic heart disease 
Intraperitoneal 
Lecithin cholesteryl acyltransferase 
Lactate dehydrogenase 
Low density lipoproteins 
Minute (s) 
Triglycerides 
Very low denisty lipoproteins 
INTRODUCTION 
- ] 
Atherosclerosis is a leading cause of death not only in developed 
countries but also in developing countries/ where rapid industrializa-
tion is changing the life style. Inspite of it, there are no known 
drugs that are able to prevent or even limit this dreadful disease. 
The term "Atherosclerosis" is derived from two Greek words 
'athere' meaning "porridge" or 'mush' and 'scleros' meaning "hard". 
This,apparently contradictory, combination describes the fact that the 
lesion begins as a soft deposit and hardens as it ages. However, 
"Atherosclerosis" has a variety of meanings depending upon the approa-
ch to the problem. According to clinicians, atherosclerosis encompa-
sses a wide variety of clinical entities which may include myocardial 
infarction, angina pectoris, cerebrovascular disease and occasionally 
changes which can be detected only on an electrocardiogram. It is 
defined by the WHO, as a variable combination of changes of the intima 
of the arteries consisting of the focal accumulation of lipids, 
complex carbohydrates, blood and blood products, fibrous tissue and 
calcium deposits, associated with medial changes. Atherosclerosis 
is, therefore, a complex and multifaceted condition which may be a 
collection of pathological states with overlapping similarities of ar-
terial abnormalities. Generally, atherosclerosis, either of aorta or 
of coronary arteries, involves the formation of lipid deposits inside 
the walls of blood vessels. These fatty substances appear mainly in 
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the smooth muscle cells and foam cells within the arterial linings. In 
space between these cells small amounts of the cholesterol can be det-
ected. Very fine fibers of a material behaving like fibrin also shows 
up within the lining as well as on its surface. At this early stage 
the forerunner of atherosclerotic lesion can be recognized in the form 
of fatty streaks. It is believed that 90 % of ail genuine forms of 
angina pectoris and myocardial infarction are associated with the 
sclerotic changes in the coronary artery (Schettler/ 1961). The arte-
ries affected with atherosclerosis exhibit thickening of arterial wall 
intima, usually hypertrophy of the media, with clearly demonstrable 
lipid deposits. Since all- these factors lead to decrease in the size 
of arterial lumen, it results in restriction of the flow of blood at 
reasonable pressure. Thus the restricted supply of oxygen and nutri-
ents to coronary muscle leads to diminished performance and finally 
heart failure. 
A. ETIOLOGY 
Many risk factors like diet, lack of exercise (Kannel, et al., 
1970), stress (Friedman, et al., 1970), cigarette smoking (Paffenber-
ger, 1970), hypertension and elevated serum lipid levels have been 
correlated with atherosclerosis. Among all these risk factors, it is 
now well established that hyperlipidemia plays very important role in 
development of atherosclerotic lesions. At first, it seems simple and 
straight forward but in fact it is not. The situation is complicated 
because: 
1. There are several different plasma lipids. 
2. The plasma lipids do not occur in free form but are combined with 
proteins to form lipoprotein complexes. Therefore, hyperlipoprot-
einemia is considered a prelude to atherosclerosis. 
The etiology of hyperlipoproteinemia may be primary or secondary. 
The primary one is due to genetically determined defects in lipid or 
lipoprotein metabolism which are exaggerated by environmental factors 
through unknown mechanisms. The secondary hyperlipoproteinemia is cau-
sed by some well defined diseases (hypothyroidism, diabetes mellitus, 
nephrotic syndrome, biliary obstruction, pancreatitis and dysglobuli-
nemia) which must be excluded in considering the etiology of the dise-
ase. Most of the risk factors, which have been correlated with ather-
osclerosis and coronory heart disease, do not correlate with stroke or 
cerebral vascular changes. Hypertension, however, is associated with 
stroke (Chapman, 1970; Paffenberger et al., 1970; Kannel et al.,1970). 
No single factor can be exclusively said to have a role in the etiolo-
gy of atherosclerosis. High blood pressure along with hypercholestero-
lemia are crucial for development of atherosclerosis (Robertson 1962). 
Certain metabolic disorders like serum uric acid (Montoye et al.,1967; 
Benedek, 1967.), lowered serum albumin (Rashev et al., 1967), lowered 
- ^ -
lipoprotein lipase (Petrova, 1967) and lowered endogenous hef^ arin 
(Velican/ 1967) have also been implicated in the etiology of 
atherosclerosis. 
B. ATHEROSCLEROSIS AND LIPOPROTEINS 
Lipids are transported in blood plasma in association with pro-
teins. Some polar lipids are transported with albumin (FFA,bile acids) 
or by specific binding proteins-retinal binding proteins. Nonpolar 
lipids are transported in large complexes containing polar lipids and 
specific proteins. These macromolecular complexes are known as lipo-
proteins. A striking feature of the plasma lipoprotein is the lability 
of its concentration in a given species in different pathological and 
physiological states and also in different animal species. Among 
mammals these differences can not be explained solely on the basis of 
the differences of the rate at which the nonpolar lipids are transpor-
ted in the blood. Even within the species/evidence for the differences 
in the metabolic pathways of a given lipoprotein class is emerging 
(Havel/ 1975). However/there is exchange and/or transfer of molecules 
between different lipoprotein particles as well as between lipopro-
teins and plasma membranes of various cells (Nilsson-Ehle et al./1980) 
during various events of lipoprotein metabolism . Lipoproteins have 
been classified mainly into four types: chylomicrons, very low densi-
- s -
ty lipoproteins (VLDL), low density lipoproteins (LDL) and high densi-
ty lipoproteins (HDL). Detailed molecular models/ suggesting a highly 
organized structure for HDL (Smith et al.,1978; Edelstein et al.,1979) 
and LDL (Day and Levy, 1976; Atkinson et al. ,1977; Smith e^ aJ^ . ,1978), 
have been proposed. The larger particles, VLDL and Chylomicrons, seem 
to consist of a central triglyceride droplet surrounded by a monola-
yer of phospholipid, cholesterol and apolipoproteins (Shen et al., 
1977). Of these lipoproteins, chylomicrons are of exogenous origin, 
derived from the dietary fat,synthesized in the gut and enter into the 
blood stream via the thoracic duct. Upon reaching the capillary bed of 
several extrahepatic tissues the chylomicrons are absorbed to the en-
dothelial surface forming an enzyme substrate complex with enzyme lip-
oprotein lipase. As a result of the activity of this enzyme, trigly-
cerides are hydrolyzed and the liberated fatty acids are taken up into 
the tissue, esterified, stored and oxidized for future energy needs. 
The transport of exogenous triglycerides in this manner via chylomic-
rons is highly efficient so that chylomicronemia ensues within few 
hours after fatty meal. This process can account for the transport of 
as much as several hundred grams of triglycerides daily. In either 
genetic or acquired deficiency of lipoprotein lipase the capacity to 
transport triglyceride is quite limited and chylomicronemia may persi-
st from meal to meal.This condition is also termed as exogenous hyper-
lipidemia. 
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The remaining three lipoprotein classes are of endogenous origin, 
normally present in fasting blood. In the fasting state majority of 
plasma triglycerides (synthesized endogenously in the liver) are con-
tained in the TG rich very low density lipoprotein and hypertrigly-
ceridemia, often but not always, means an increase of VLDL, which is 
sometimes associated with an increase of both HDL- and LDL- TG. The 
function of plasma lipoproteins in TG transport is well documented 
(Havel, 1972). The main function of VLDL is to transport TG from 
liver to peripheral tissues. In a manner analogous to the synthesis 
of chylomicrons from exogenous lipids in the intestinal mucosa, the 
TG rich VLDL are synthesized in the endoplasmic reticulum of 
parenchymal cells of liver and intestinal mucosa. The VLDL 
synthesized in the liver is termed as nascent VLDL, the composition 
of the core of the nascent VLDL closely resembles whereas the surface 
monolayer differs from the plasma VLDL (Hamilton, 1973). Several evi-
dences indicate that the surface of the lipoprotein is modified once 
they enter the extracellular environment. This modification depends 
upon the exposure to a large amount of HDL, thus hepatogenous VLDL 
acquires C-apoproteins from HDL. The cholesterol content in the sur-
face also increases while that of phospholipid falls (Hamilton, 1973). 
The LPL-activating apolipoprotein apo C increases the affinity of the 
particle with lipoprotein lipase and enhances the catalytic rate 
of the enzyme on component triglycerides (Fielding/1973; Nilsson-Ehle, 
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et ^ .,1980). The hydrolysis of the triglyceride core of VLDL nor-
mally occurs rapidly at the surface of blood capillaries in several 
tissues (most notably adipose tissue and heart),where most of the tri-
glyceride fatty acid is taken up into the tissues for storage or 
oxidation. The partially degraded particles (remnants) are rapidly 
metabolized by the liver- These remnant particles, whether derived 
from chylomicrons or VLDL, contain only a fraction of triglycerides, 
phospholipids and apo-C originally present but they retain all of 
the cholesterol esters and apo-B and the bulk of the cholesterol. 
The liver accounts for removal of almost all the remnant chole-
sterol ester and cholesterol (Bergman _et ^ . , 1971). It has been 
suggested that VLDL remnants may follow two pathways: (i) incorpo-
ration as unit into the liver and (ii) conversion, also presumably 
involving the liver, to LDL (Faergeman et al., 1974). In humans LDL 
are thought to be the major catabolic product of VLDL (Bilheimer 
£ t ^ . / 1972). The level of VLDL and its triglycerides can be affected 
by hormones which increase (norepinephrine, growth hormone) or decre-
ase (insulin) the supply of fatty acid used for hepatic triglyceride 
synthesis. 
Since cholesterol esters and cholesterol are major components of 
atherosclerotic lesions, the interaction of the cholesterol carrying 
lipoproteins in plasma with the cells of the arterial wall seems to be 
important. An increased level, of cholesterol carrying lipoprotein-
LDL is associated with an increased risk of developing atherosclerot-
ic cardiovascular disease . As LDL levels increase more LDL 
presumably filters into subintimal regions and the cholesterol 
carried in LDL accumulates within the arterial wall (Vega et al./1985) 
The contribution of LDL to atherosclerosis, however, may not be deter-
mined solely by plasma LDL concentrations. The disturbances in metabo-
bolism of LDL may also affect the atherogenecity of this lipoprotein. 
For example, it has been proposed that normal LDL must be 
modified before it can induce the development of foam cells (Brown 
and Goldstein, 1983). Other metabolic abnormalities may also render 
LDL more atherogenic. There are several reports of such abnormalities 
(Sniderman, et al., 198.0; Brunzell jet al., 1983; Teng et al., 1983; 
Vega and Grundy, 1984). There . is also considerable evidence that 
elevated level of plasma triglyceride is also a risk factor for IHD. 
Since LDL and VLDL both are considered to be atherogenic, it seems 
desirable to develop therapeutic agents which specifically lower 
these atherogenic lipoproteins. Since total serum cholesterol 
concentration represents a composite of that of all serum liporoteins, 
measuring serum cholesterol alone does not allow a distinction 
between reduction in atherogenic or nonatherogenic lipoproteins or 
both, to be made. The removal of HDL from the blood seems to be 
accomplished primarily by the liver (Rachmilewitz _et ^ . , 1972). 
Therefore, cholesteryl esters carried by HDL or in remnants of TG rich 
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lipoproteins are transported to the organ in which cholesterol is 
excreted from the body. The cholesterol esters that enter LDL, 
either from catabolism of TG rich lipoproteins or by transfer 
from HDL/ may have a different fate. Studies of Sniderman et_ ah. 
(1974) suggested that removal of LDL from blood is not impaired by 
hepatectomy and a high affinity receptor for LDL is present on the 
surface of fibroblasts (Brown and Goldstein, 1974). Binding to this 
receptor is rapidly followed by hydrolysis of the esters and the 
apo-B (Goldstein & Brown, 1977). This receptor mediated endocytosis 
results into the elimination of LDL particles from the blood 
circulation. Different lipoproteins have quite different functions in 
transport of cholesterol. LDL serve to supply cholesterol (mainly as 
ester) needed for membrane and hormone synthesis, from liver to 
peripheral tissues,whereas HDL efficiently transports cholesterol from 
various tissues to the liver for final elimination (Glomset, 1979). 
This reverse cholesterol transport renders HDL to be antiatherogenic 
agent. However, LDL cholesterol is ultimately derived from dietary 
cholesterol transported in chylomicrons, or from cholesterol secreted 
from the liver in VLDL (plus a small amount secreted in HDL). The 
key roles for LCAT and for HDL in the transport of cholesterol to the 
liver are also suggested by the genetic disorders of LCAT deficiency 
and Tangier disease, whereas that of LDL may find negative expression 
in abetalipoproteinemia ( Havel, 1975). Because of the inverse 
10 
association of HDL with the incidence of coronary heart disease, as 
deinonstrated by a number of clinical and epidemiological studies 
(Miller and Miller, 1975; Bahler et_ aJ^ ., 1980; Tyroler, 1980), major 
interest has been focussed on this lipoprotein (Miller 1980a). 
High density lipoproteins form a heterogenous group of particles 
which can be divided/ on the basis of density, into two subfractions 
HDL and HDL . The concentrations of these subfractions vary indep-
endently of each other and they have separate metabolic pathways 
(Nikkila, 1981). HDL is larger and less dense and contains more 
phospholipid and free cholesterol than HDL (Shen et aJ^ ., 1977). Their 
concentration is influenced by many physiologic variables such as hor-
mones, diet, sex and physical activity- The variation in total HDL 
concentration reflects mainly those of HDL subfraction (Gidez et al., 
1982). HDL^ is supposed to be the component that is most closely 
related with atherosclerotic vascular disease (Hammett et al., 1979; 
Miller, 1980b). In contrast to other lipoproteins, HDL is not turned 
over as a single compound. Its constituents may enter and leave the 
mother particle at different rates and undergo exchange or bidirect-
ional shuttling between HDL and other lipoproteins or cell membranes. 
The primary HDL particle is elaborated by liver and intestine and 
secreted into blood as disc shaped nascent HDL. When comes into circu-
lation, this particle combines with apo A-I and donates apo C and apo E 
to chylomicrons and VLDL. After esterification of cholesterol by LCAT 
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enzyme, it takes a spherical form and becomes HDL (Glomset/ 1980). 
During subsequent steps of intravascular metabolism, HDL acts as an 
acceptor of cholesterol, phospholipids and apoproteins that are 
released during degradation of TG-rich lipoproteins (chylomicrons and 
VLDL) by lipoprotein lipase at extrahepatic capillary beds. Upon 
this process, HDL^ is transformed into HDL (Patsch ^  al^ -/ 1978). The 
rate of this reaction is the key determinant of plasma HDL and total 
HDL concentrations, as indicated by close positive correlation between 
lipoprotein lipase activity and HDL (or total HDL) levels (Nikkila et 
al., 1978). The HDL concentration, on the other hand, is not related 
to the lipoprotein lipase .activity or shows a weak negative correla-
tion (Taskinen and Nikkila, 1981). 
There is a preliminary evidence for the role of hepatic lipase 
in the hepatic uptake of HDL cholestrol and phospholipids (Nikkila 
et al., 1980). Some authors have suggested that only HDL is selecti-
vely degraded by the hepatic lipase, which possesses a high phospholi-
pase activityCVan Tol et^  aJ^ ., 1980). It has been speculated that HDL 
could loose only part of its surface lipid in the liver and be conve-
rted back to HDL which is returned to plasma and starts the circle 
again. A shuttle of HDL and HDL between peripheral tissue and liver 
would nicely fit the proposed role of HDL in "reverse" cholesterol 
transport (Glomset, 1970). The process of conversion of plasma HDL 
to HDL , involving neutral lipid exchange and role of triglyceride 
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lipases/ has recently been documented by Deckelbaum et al. (1986). 
Thus total plasma HDL concentration is regulated by the following 
factors- (1) the rate of input of nascent HDL into plasma (2) the 
activity of lipoprotein lipase at peripheral capillaries (3) the 
activity of hepatic lipase in the liver. 
Further regulatory sites may exist particularly for the 
synthesis and catabolism of apo A-I and apo A-II. Diet, exercise and 
many hormones probably influence HDL through the two lipolytic ezymes. 
C. HYPOLIPIDEMIC COMPOUNDS 
The implication of blood lipids as a contributing factor 
in the pathogenesis has led to widespread search for compounds which 
safely and effectively control the concentration of cholesterol and 
triglycerides in the blood and hopefully in the tissues. Modern 
medicine is faced with the challenge of helping hundreds of millions 
of individuals with undetected coronary atherosclerosis, many of whom 
will eventually develop ischaemic heart disease and probably die as a 
consequence. To reduce the incidence of clinically unrecognized 
coronary atherosclerosis, a risk free, noninvasive, and so far 
nonexistent method of detecting the progress of coronary atherosclero-
sis in man is long overdue. Until such a method becomes available the 
most feasible alternative is to substitute an animal model in which 
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coronary atherosclerosis can be induced to study its progression, 
regression or arrest. 
The involvement of cholesterol in the atherogenic process has 
led to various forms of treatment intended to reduce serum cholesterol 
concentrations and/ consequently/ the high incidence of early morta-
lity/ found in cases of familial hypercholesterolemia. The use of 
low fat and low cholesterol diet is the oldest therapeutic approach to 
reduce the risk of coronary heart dieseae. Since diet therapy alone 
does not seem to be very effective/ the use of hypocholesterolemic 
agents alongwith dietary regimes is often required. Serum cholesterol 
can be effectively lowered by using inhibitors of HMG Co-A reductase/ 
the rate limiting enzyme of cholesterol biosynthesis. In addition 
stimulation of cholesterol excretion and degradation to bile acids and 
inhibition of absorption of dietary cholesterol and biliary choleste-
rol may also reduce blood cholesterol level upto some extent but these 
manipulations appear to be less feasible. Using animal systems a large 
spectrum of hypolipidemic drugs has been investigated differing in 
their degrees of efficacy and modes of action. They may decrease serum 
lipid levels by impairing lipid absorption/ lipoprotein synthesis or 
release, or by stimulating lipid or lipoprotein catabolism (Sirtori 
et _al., 1973). 
Clofibrate, Nicotinic acid, esterogenic substances, Triparanol, 
Hydroxylamines, Mevinolin and Probucol are the examples of the inhibi-
1^ 
tors of cholesterol biosynthesis. Clofibrate, ethyl-p-chlorophenoxy 
isobutyrate (CPIB) is an effective hypolipidemic drug,most widely used 
in clinical practice. Thorp and Waring (1962) first reported the in-
hibition of hepatic cholesterol synthesis in CPIB-fed rats.The ability 
of CPIB to lower post prandial plasma optical density as well as trig-
lycerides and lipoprotein suggested an action on lipoprotein lipase 
(Strisower and Strisower, 1964). CPIB has been shown to inhibit chol-
esterol biosynthesis at the step involving conversion of acetate to 
mevalonate (Gould et al.,1966) thereby inhibiting overall synthesis of 
steroids. CPIB also affect several other metabolic pathways. Marago-
udakis (1969) reported inhibition of fatty acid synthesis by CPIB tre-
atment. Tolman et al. (1970) reported stimulation of lipoprotein 
lipase activity in adipose tissue. Stimulation of adenyl cyclase 
activity following CPIB treatment has also been reported (Greene 
e^^.,1970). CPIB inhibits liver lipid biosynthesis and induces liver 
cholesterol depletion. Increase in lipoprotein lipase activity results 
into increased catabolism of VLDL and elavated HDL cholesterol level, 
thus it helps in mobilization of tissue cholesterol. Borreback et al., 
(1979) reported increased levels of hepatic acyl-Co A hydrolase acti-
vities in clofibrate fed rats. Hazzard et al. (1984) demonstrated 
significant decrease in plasma cholesterol and triglycerides, VLDL-
cholesterol and triglycerides and an increase in HDL-cholesterol upon 
clofibrate feeding. However,it was associated with increase in reports 
of nausea. 
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Various clofibrate analogues have also been described as 
hypolipidemic and hypocholesterolemic agents. Halofenate/ structurally 
related to clofibrate is a hypolipidemic and hypouricemic drug (Sirto-
ri et al./1972). It has been found to be effective in lowering serum 
triglycerides in rat (Kritchevsky and Tepper/ 1972). Another a.ialogue 
3[4-(l-Othoxycarboxyl-l-methylethoxy)phenyl]-5(3 pyridyl)-l,2,4-oxadi-
zole (AT-308) is effective in lowering serum cholesterol of normal 
rats significantly. Methyl clofenapate (Craig and Waltom, 1972) and 
2-[4(4'-chlorophenoxy)-phenoxyl] propionic acid or HCG-004 (Granzer 
and Nahm/ 1973) have also been reported to be hypocholesterolemic and 
hypolipidenic compounds. 
Bezafibrate (a fibric acid derivative) is a new hypolipidemic 
drug. Recently it has been reported to lower plasma triglycerides in 
hypertriglyceridemic patients (Eisenberg et al., 1984). It was also 
found effective in reversing most/ if not all/ of the plasma lipopro-
tein abnormalities found in these patients. Reports are also available 
to snow its stimulating effect on enzymes/ lipoprotein lipase and 
hepatic lipase (Vessby et al./ 1982) during treatment of hypertrigly-
ceridemic patients. This drug is also known to accelerate LDL degrada-
tion via the receptor pathway (Stewart £t aJ^ . / 1982). Gavish et al. 
(1986) reported a decrease of plasma cholesterol and triglycerides, 
VLDL-cholesterol/ LDL-cholesterol and an increase of HDL-cholesterol 
alongwith the increase in postheparin plasma lipase in patients with 
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type II A and type II B hyperlipoproteinaemia in response to bezafibr-
ate therapy. 
Mevinolin and compactin (ML-236B) belong to a new class of cho-
lesterol lowering drugs that appear highly effective in relatively low 
doses. The primary action of these drugs is to competitively inhibit 
HMG Co-A reductase. These drugs have been used to reduce plasma chole-
sterol levels in many animal species (Alberts et al., 1980; Kovanen et 
al., 1981; Tobert et^  aJ^ -' 1982). Clinical studies have shown that 
mevinolin and compactin effectively reduce plasma levels of LDL in 
normal subjects (Tobert et al./1982) and in patients with heterozygous 
familial hypercholesterolemia (Yamamoto et^  al^ . / 1980; Bilheimer et 
al./ 1983). The inhibition of cholesterol synthesis by mevinolin 
appears to trigger a compensatory increase in the receptor mediated 
catabolism of LDL resulting into the increased utilization of lipo-
protein cholesterol by the cells (Grundy and Bilheimer/ 1984). 
Probucol (4,4'(isopropylidenedithio) bis(2-6-di-t-butylphenol)) 
or DK-581 has been reported to be effective for the treatment of hype-
rcholesterolemia. It effectively reduces plasma cholesterol by inhib-
iting cholesterol biosynthesis in human and a number of animal 
species (Miettinen and Toivonen/1975; MartZ/1979;Simson et. al^ . / 1981). 
Probucol also decreases the activity of plasma lipoprotein lipase and 
HDL- and LDL-cholesterol concentrations in rat (Strandberg et al./ 
1981). A possible mechanism of action of probucol has been proposed 
20 
by Balasubramanium et al. (1981) involving its effect on LDL and HDL 
metabolism and on the key enzymes of cholesterol metabolism. The drug 
triparanol is also an inhibitor of cholesterol biosynthesis and it is 
also found to interfere with the luminal absorption of cholesterol 
(Bhattacharya and Eggen 1984.) 
A derivative of thiophenol/ DH-990 has also been reported to 
lower normal serum cholesterol levels in mice, rats and monkeys (Renzi 
et al./ 1974). Tibric Acid (2-chloro-5-(cis-3/5-dimethyl-piperidono-
sulfonyl) benzoic acid) also reduces plasma lipids in normal rats in 
doses as low as 5 mg/kg/day (Pereira and Holland, 1974). Tiadenol, 
(bis(hydroxyethylthiol) 1-10 decane), is an absorbable hypolipidemic 
agent (Baggio, et al., 1979). Tiadenol treatment was remarkably 
effective in inhibiting fructose induced hypertriglyceridemia. Its 
mode of action differs from that of clofibrate and related compounds 
(Franceschini, et al./ 1981). 
Buchanan and Sprancmanis (1973) have synthesized a series of 
hypocholesterolemic 5-methyltetrazole derivatives: two of them are 
especially active in lowering cholesterol levels in normal rats by 47 
and 30 %. 
Among Bile acid sequestrants, one type of hypocholesterolemic 
drugs whose mechanism of action is understood, is the kind that binds 
bile salts and thereby decreases cholesterol absorption. Anion 
exchange resins are the good examples. They bind bile acids in the 
intestinal lumen and prevent their reabsorption resulting into their 
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excretion in the faeces. These sequestering agents, thus, interfere 
with the enterohepatic circulation of bile acids. Since bile acids 
are synthesized in the liver from cholesterol, cholesterol catabolism 
is accelerated. As a result of which plasma cholesterol concentration 
decre^es. When administered to human subjects, these resins are known 
to alter lipoprotein composition such that LDL are smaller, more 
dense, and have a decreased cholesteroliprotein ratio (Witztum et 
al., 1979). Bile acid sequestrant resins are widely used in the 
therapy of hypercholesterolemia as they specifically lower plasma LDL 
concentration by enhancing the fractional catabolic rate (FCR) of LDL 
via receptor mediated pathway (Slater et^  al., 1980; Kovanen et al., 
1981; Hui et aJ^ ., 1981; Chao et_ aJ^ ., 1982). Examples of such lipid 
lowering agents are cholestyramine, colestipol and secholex. 
Cholestyramine was found to reduce plasma cholesterol levels in 
man and animals (Glueck et al., 1971; Fellin et al^ ., 1975). Cholesty-
ramine induced changes in LDL composition and metabolism have also 
been reported using guinea pigs as animal models (Witztum et al., 
1985). 
Colestipol is an insoluble copolymer of tetraethylene pentamine 
and epichlorohydrin. It was found effective in decreasing reabsorption 
of bile acids and enhancing their faecal excretion (Parsons, 1972). 
Colestipol treatment resulted in a reduction of total cholesterol in 
plasma as well as in tissues (Good et al., 1973; Miller et al., 1973). 
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Hazzard et_aL. (1984) reported significant decrease in plasma and LDL 
cholesterol while an increase in VLDL-TG was observed after colestipol 
treatment in hyperlipidemic volunteers. However/ this treatment was 
associated with reports of constipation and nausea. Secholex has been 
tested alone and in combination with clofibrate (Evans et al., 1973; 
Howard and Evans/ 1974). The combined therapy was found more effective 
as compared to secholex alone. 
D. GENESIS OF THE PRESENT WORK 
Hyperlipidemia has been well recognized in the etiology of 
atherosclerotic lesions. Therefore, a logical therapeutic approach 
could be the search of compounds which could safely and effectively 
lower the lipids in blood and hopefully in tissues. Since more than 
70% of the total input body cholesterol is derived from de novo 
synthesis in human (Dietschy and Wilson, 1970), it is expected that 
compounds inhibiting cholesterol biosynthesis may prove more useful in 
combatting hypercholesterolemia. The most suitable target for this 
inhibition would be HMG Co-A reductase, the rate limiting enzyme in 
cholesterol biosynthesis (Rodwell et_ al_., 1976). HMG is known to 
inhibit cholesterogenesis between HMG Co-A and mevalonate (Rabinowitz 
and Gurin, 1954) and competitively inhibits the enzyme HMG Co-A redu-
ctase (Fimognari and Rodwell, 1965). 
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During the last two decades/this laboratory is actively engaged 
in gaining an insight into the mechanism of hypolipidemic action of 
HMG. 
1. The oral administration of HMG in normal as well as hypercholester-
olemic rats resulted in significant reduction of serum cholesterol. 
The combined feeding of cholesterol and HMG also significantly 
reduced the serum and hepatic cholesterol levels (Beg and Siddiqi, 
1967; Beg et al^ 1968) and it had no hepatotoxic effect at the 
microscopic level. The animals receiving fat-rich cholesterol diet 
showed a maximum significant reduction in ester cholesterol and 
triglycerides after HMG treatment (Beg and Siddiqi, 1968). 
2. HMG was found to inhibit hepatic cholesterogenesis (Beg and Lupien 
1972). Saleemuddin and Siddiqi (1972) showed that i.p. administr-
ation of HMG caused an increase in hepatic HMG Co-A hydrolase acti-
vity and suggested a physiological control mechanism for choleste-
rol biosynthesis. 
3. HMG had been shown to exert a protective effect in experimental 
atherosclerosis in rabbits. It had no significant effect on serum 
enzymes like GOT, GPT, LDH, CPK and alkaline phosphatase (Lupien et 
al., 1973). In an independent study Yusufi and Siddiqi (1974) 
established hypolipidemic property of HMG in rabbits. As all serum 
lipids were reduced, it was suspected that hypolipidemic action of 
HMG could be mediated through its action on lipoproteins. 
4. In alcohol induced lipemia in man,HMG markedly reduced elevation of 
serum triglycerides, LDL and phospholipids (Yousufzai et al.,1976). 
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5. In an effort to demonstrate the hypolipidemic action of HMG under 
varied dietary and experimental conditions/it was demonstrated that 
HMG effectively counteracts the lipemic and atherosclerotic res-
ponse of massive doses of vitamin D and there is a lowering of 
serum LDL (Yousufzai and Siddiqi, 1976a). HMG is more effective 
against hypertriglyceridemia in rats (Yousufzai & Siddiqi, 1975b). 
6. HMG administration alongwith atherogenic diet in rats significantly 
decreased cholesterol and phospholipids of serum/ aorta and heart. 
The triglyceride levels in serum, liver and epididymal fat were 
significantly decreased (Yousufzai and Siddiqi/ 1977a). The effect 
of HMG with different carbohydrate diets appeared to be independent 
of the type of the carbohydrate (Yousufzai and Siddiqi, 1977b). 
7. HMG induced lowering of lipid parameters in serum /&-lipoproteins 
and liver would be due to either inhibition of VLDL synthesis or 
VLDL triglyceride release in liver. Since HMG failed to prevent 
orotic acid induced fatty liver (Yousufzai and Siddiqi, 1977c), it 
ruled out the possibility of HMG inhibiting the release of VLDL and 
LDL. 
8. HMG has a high LDj-„without toxic or teratogenic effects (Savoic and 
Lupien 1975a) and is promptly absorbed from the gut (Sovoic and 
Lupien 1975b). In a double blind trial in hypercholesterolemic 
patients, effect of different doses of HMG on plasma and LDL were 
studied (Lupien et^  aJ^ ., 1979). The patients responded well to 
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HMG treatment without any evidence of adverse clinical or biologi-
cal effect. All patients maintained excellent compliance to medica-
tion suggesting that HMG/ because of its lack of toxicity, may be 
useful as an adjuant to diet in treatment of familial hypercholes-
terolemia. 
EXPERIMENTAL 
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A, MATERIALS 
I. Chemicals: 
The chemicals used in the present study were obtained from the 
sources given against their names. 
Chemical 
Acetyl acetone 
1,2/4-Amino naphthosulfonic acid 
Bovine serum albumin 
Cholesterol 
Cholic acid 
Dextran sulphate 
Digitonin 
Diphenyl carbazide 
Diphenyl carbazone 
Heptane 
Hydrogenated vegetable oil 
3-Hydroxy-3methyl glutaric acid 
Orthophosphoric acid 
Source 
Koch-Ligh Laboratories, England. 
Centron Res. Lab., Bombay. 
Sigma Chem. Co., USA. 
J.T. Baker Chem. Co., USA. 
E.Merck, India. 
Sigma Chem. Co., USA. 
Sigma Chem. Co., USA. 
Wilson Laboratories, India. 
Veb Jenapharm Laborchemie, Apolda, 
Glaxo Laboratories, India. 
Hindustan Lever Ltd., India. 
Mann Research Laboratories, USA. 
Glaxo Laboratories, India. 
E. Merck, India. Perchloric acid 
Potassium dihydrogen orthophosphate B.D.H.,India. 
Silicic acid Sigma Chem. Co., USA. 
Sodium metaperiodate Loba-Chemie, India. 
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Chemical 
Triethanolamine 
Triolein 
Tris (hydroxymethyl) aminomethane 
Source 
Ferak Laboratory GMBH, GDR 
Sigma Chem. Co., USA. 
Fluka, Switzerland. 
II. Animals: 
Male albino rats, used in the present study, were purchased 
from a local animal supplier. 
III. Diet: 
The following diets were used during the study, 
(i) Basal diet: Hind Lever Rat Feed was obtained from Hindustan 
Lever Ltd. India, 
(ii) Fat-rich cholesterol diet: Basal diet was mixed with hydroge-
nated vegetable oil (5%), cholesterol (2%) and cholic acid 
(1%) (Beg and Siddiqi, 1968). 
B. METHODS 
Animals were conditioned for two weeks on basal diet prior to 
their transfer on experimental diet. All the diets and water were 
given ad libitum. Twenty rats were made hyperlipidemic by feeding them 
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fat-rich cholesterol diet for three weeks. These hyperlipidemic rats 
were divided into two groups each of ten rats and were returned to 
basal diet. Animals in the treated group recievd 20 mg HMG/kg body 
weight/day/ i.p.,in 1ml saline for twelve days. Animals in the corres-
ponding control group were given an equal volume of saline for the 
same period. The animals were fasted overnight/ anaesthetized with 
ether/ and blood was withdrawn by cardiac puncture. The heart and 
liver were excised out/ quickly washed/ weighed and dropped into ice 
cold 0.25 M sucrose solution. Blood was allowed to stand for 4 h. at 
room temp and centrifuged at 3/000 rpm for 5 min at 4 C. 
I. Fractionation of Serum Lipoproteins: 
Serum lipoproteins were fractionated by the precipitation method 
as described by Onanogbu and Lewis (1976).To 1 ml of seruiii/ in a glass 
centrifuge tube, were added 0.05 ml of 22.2% calcium chloride and 0.04 
ml of 5% dextran sulphate. The contents of the tube were mixed thoro-
ughly and the tube was left at 4 °C for 24 h. The contents of the 
tube were centrifuged at 2/000 rpm for 25 min at 4°C. Supernatant was 
separated out and used for analysis of HDL lipids. The precipitate was 
redissolved in 1 ml of 0.9% sodium chloride and treated with 0.1 ml 
of 13.0% potassium oxalate and kept at 4 "c for 24 h. After centri-
fugation/ at 3/000 rpm for 10 min/ the supernatant containing LDL and 
VLDL was used for lipid analysis. 
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II. Quantitative Determination of Triglycerides: 
Triglycerides were estimated in serum and lipoprotein fractions 
according to the method of Gottfried and Rosenberg (1973) and Levy 
(1972). 0.5 ml of the test samples were taken in glass test tubes. 
2.0 ml of heptane, 3.5 ml of isopropanol and 1.0 ml of 0.08N sulfuric 
acid were added to all tubes. At the same time 0.5 ml of water was 
taken as the control sample and was treated in a similar way as the 
test samples. 
The contents of each tube were mixed for 20 sec on a cyclomixer 
and allowed to stand for 5 min at room temperature. The upper heptane 
layer was carefully transferred to clean tubes. 0.5 ml of this extra-
ct was treated with 4.0 ml of isopropanol and 2 drops of 6.25 M 
potassium hydroxide and mixed well. The samples were heated at 70°C 
for 10 min followed by the addition of 0.4 ml of periodate reagent and 
2.0 ml of acetylacetone reagent. The tubes were again heated for 10 
min at 70°C, cooled to room temperature and the absorbance was read 
at 425 nm against the blank set at zero absorbance in a "spectronic 
20" spectrophotometer. 
For standardization stock standard of 1000 mg triolein/100 ml 
isopropanol was prepared. Calibration curve was drawn using working 
standards of 50, 100, 200, 300 and 350 mg/100 ml concentrations. The 
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standard samples were analyzed exactly like the test one, except that 
3.0 ml of isoproponol and 0.5 ml of water were added in the extrac-
tion step instead of 3,5 ml of isopropanol. It was found that an 
optical density of 0-5 was equivalent to 300 mg/100 ml triglyceride 
concentration. 
III. Quantitative Determination of Total Lipids: 
The serum and lipoprotein total lipids were determined by the 
method of Frings et al. (1972). 0.1 ml of the test sample and 2.0 ml 
of concentrated sulfuric .acid were added to a glass test tube. At 
the same time 0.1 ml of standard solution (700 mg olive oil/100 ml of 
absolute ethanol) and 2.0 ml of concentrated sulfuric acid were added 
to another tube. The contents of the tubes were mixed well and heated 
in a boiling water bath for 10 min and then cooled to room tempera-
ture. 0.1 ml aliquot of each tube was then transferred to a clean 
tube. 0.1 ml of concentrated sulfuric acid was taken as 'Blank'. To 
all tubes 6.0 ml of phosphovanillin reagent (1.2 g of vanillin disso-
lved in 200 ml of water and made upto 1 lit with orthophosphoric 
acid) was added with thorough mixing and the tubes were incubated at 
37 C for 15 min. The absorbance was read at 540 nm in a "spectronic 
20 spectrophotometer using Blank to set zero absorbance. 
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The amount of total lipids was calculated as follows. 
absorbance of Test sample 
Total lipids (mg/dl) = x 700 
absorbance of Standard 
IV. Quantitative Determination of Phospholipids: 
Phospholipids were determined by the method of Bartlett (1959) 
as modified by Marinetti (1962). The lipoprotein or serum sample 
(0.3 ml) was delivered into centrifuge tubes containing 3.0 ml of 
water. Five ml of freshly prepared 10% TCA (w/v) solution were added 
to all tubes. The tubes were allowed to stand for 10 min and 
centrifuged at 3/000 rpm for 15 min- The supernatant was decanted and 
the tubes were inverted on filter paper until practically all the 
supernatant was removed. The precipitates were digested with 1.0 ml 
of perchloric acid (70%) on an electric digestion unit for about 45 
min. On cooling to room temp./ 7.0 ml of distilled water were 
added to all tubes followed by the addition of 1.5 ml of ammonium 
molybdate (2.5%/ w/V) and 0.2 ml ANSA reagent (0.25%/ w/v). The 
samples were mixed on cyclomixer/ and heated in a boiling water bath 
for exactly 7 min/ cooled and read after 20 min at 660 nm in a 
"Spectronic 20" spectrophotometer. A calibration curve was prepared 
using potassium dihydrogen orthophosphate (KH PO ) as standard (2 mg 
phosphorus/100 ml). Suitable aliquots of 0.1 ml-1.0 ml were diluted 
to 8.0 ml with 1.0 ml of perchloric acid and 6.9-6.0 ml of distilled 
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water and treated in the same manner as the test samples. Under the 
experimental conditions/ an optical density of 0.5 was equivalent 
to 16/jg of phosphorus. The phospholipid values were obtained after 
multiplying the phospholipid phosphorus by a factor of 25. 
V. Quantitative Determination of Cholesterol: 
Total/ free and esterified cholesterol were estimated by the 
method of Loeffler and Mc Dougald (1963) in serum and lipoproteins. 
To glass centrifuge tubes/ containing 4.8 ml isopropanol, were added 
0.2 ml of the test sample and 0.2 ml of the standard (200 mg 
cholesterol/100 ml isopropanol). The contents were mixed, allowed to 
stand for 5 min and centrifuged at 3/000 rpm for 10 min. 
For total cholesterol, 1.0 ml of the test supernatant was 
taken in glass test tubes and treated with 2.0 ml of ferric chloride 
reagent (70 mg of ferric chloride hexahydrate/100 ml of glacial 
acetic acid) mixed immediately followed by the addition of 2.0 ml 
of cone, sulfuric acid with thorough mixing. For reagent blank/ 1 ml 
of isopropanol was used instead of test supernatant. After 5 min the 
absorbance was read at 550 nm in a "Spectronic 20" spectrophotometer 
using Blank to set zero absorbance. 
For the determination of free cholesterol and cholesterol ester 
2.0 ml of the supernatant was treated with 4.0 ml of acetone and 2.0 
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ml of digitonin solution (1.0 g of digitonin dissolved in 60 ml of ab-
solute ethanol/ diluted to 100 ml with water and mixed well). The 
tubes were allowed to stand in an ice bath for 30 min and then centri-
fuged for 10 min at 4,000 rpm. The supernatant was decanted complete-
ly. The precipitate was again washed with 5.0 ml of acetone and 
dissolved in 1.0 ml of isopropanol. At the same time, 1.0 ml 
isopropanol was taken in a clean tube to serve as 'Blank'. To 
all the tubes, 2.0 ml of ferric chloride reagent and 2.0 ml of 
cone, sulfuric acid were added and the contents were mixed well. After 
5 min, the absorbance was read at 550 nm in a "Spectronic 20" spectro-
photometer using blank to set zero absorbance. 
The total, free and esterified cholesterol were calculated 
as follows: 
absorbance of Test sample 
Total cholesterol (mg/dl) = x 200 
absorbance of Standard 
absorbance of Test sample 
Free cholesterol (rag/dl) = x 100 
absorbance of Standard 
Cholesterol esters (mg/dl)= Total cholesterol-Free cholesterol 
VI. Determination of the Activity of Hepatic Lipase: 
The livers, excised from the animals, were homogenized in a 
medium containing 0.25 M sucrose and 10 mM Tris/HCl, pH 7.4. The 
protein was estimated in the homogenates by the method of Lowry ^  ^ . 
(1951). For the assay of lipase activity, the substrate used had the 
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following composition: 0.2 M Tris, 0.75 M NaCl, 0.4% gum arable, 0.5% 
BSA and 2.26 mM triolein. Prior to use it was emulsified by sonication 
in MSE "Soniprep 150". 0.01 ml aliquots of liver homogenate were added 
to stoppered glasstubes containing 0.09 ml of preincubated substrate. 
o 
The tubes were incubated on a shaking water bath maintained at 37 C 
for 25 min. The reaction was stopped by adding 6 ml of the solvent 
containing chloroform-heptane-methanol (200:150:7, v/v/v) to the reac-
tion mixture. Free fatty acids were extracted and estimated in the 
reaction mixture by the method of Hron and Menahan (1981). 
About 330 mg of silicic acid was added to each reaction mixture 
and the tubes were shaken 30 times by hand and allowed to stand for 15 
min at room temperature. The tubes were again shaken 6 times and cen-
trifuged at 4,000 rpm for 5 min. The supernatant containing the extr-
acted free fatty acids was decanted into another tube containing 2.0 
ml of freshly prepared Cu-TEA solution [0.05 M Cu(NO2)2/0.1 M trieth-
anolamine, pH 8.1, saturated with NaCl (app. 33 g/100 ml)]. The tubes 
were shaken vigorously on a mechanical shaker for 20 min and centrifu-
ged for 5 min at 4,000 rpm, 4.0 ml of the upper organic layer was 
then treated with 2.0 ml of the colour reagent (0.5% solution of a 
mixture of diphenylcarbazone and diphhenyl carbazide (5:95) in met-
hanol). The resulting colour was read after 10 min at 550 nm in 
"Spectronic 20" spectrophotometer against a reagent blank (containing 
no substrate but buffer) run in the same way as the test sample. The 
amount of free fatty acids was calculated from the calibration curve. 
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prepared by using standard solution of palmitic acid in chloroform 
(5/J moles/ml).The activity of hepatic lipase was expressed as u moles 
FFA/mg/hr. 
VII. Determination of the Activity of Myocardial Lipase: 
The hearts were homogenized in a medium containing 0.25 M 
sucrose and 10 mM Tris/HCl, pH 7.4. The protein was estimated in heart 
homogenates by the method of Lowry et al. (1951). The aliquots of this 
homogenate served as the source of lipase. 
The reaction mixture had the following composition: 20 mg 
Triolein, 5.0 ml, 20% BSA and 2.5 ml, 0.1 M NaCl (Vajreswari and 
Tulpule, 1980). It was emulsified by sonication in a MSE "Soniprep 
150". The lipolytic activity was determined by adding 0.025 ml of 
homogenate to glass stoppered tubes containing 0.075 ml of preincu-
bated reaction mixture at 37°C. The tubes were shaken for 25 min on a 
shaking water bath maintained at 37°C. The reaction was stopped by 
adding 6 ml of the chloroform-heptane-methanol (200:150:7, v/v/v) 
solvent. The enzyme activity was measured by estimating amount of FFA 
released, specti^hotomepically as described earlier by the method of 
Hron and Menahan (1981). The activity was expressed as ja moles 
FFA/mg/hr. 
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C. TREATMENT OF DATA: 
Unless mentioned otherwise/ the percent reduction has been 
calculated in the following manner. 
Value of control group-value of HMG treated group 
Percent reduction^ x 100 
value of control group 
Statistical significance was calculated by Mann-Whitney U-test/ using 
a microcomputer software. 
RESULTS 
AND 
DISCUSSION 
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The recognition and treatment of risk factors is considered 
more and more desirable for the primary and secondary prevention of 
coronary heart disease (CHD). Among risk factors, the most important 
biochemical correlate of CHD is hypercholesterolemia with elevated 
levels of VLDL and LDL. Epidemiological studies have indicated an in-
verse relationship between the levels of serum HDL and the incidence 
of CHD. The intimate association between atherosclerosis and coronary 
thrombosis is well established.Because ot the unsatisfactory reduction 
in plasma cholesterol levels by diet therapy alone,resort has to be 
made to drug therapy. Since all the known hypolipidemic agents are 
not of clinical use, there is a need to search for ideal hypolipidemic 
drug having none of the side effects. 
3-Hydroxy 3-methylglutaric acid (HMG) has been reported from this 
laboratory as an effective hypolipidemic agent for the control and 
treatment of atherosclerosis. It has a high LD and does not exhibit 
any toxic or teratogenic effect. Although much work has been done to 
establish hypolipidemic action of HMG (Beg et al^ ., 1968; Yousufzai £t 
al., 1976a,b; Yousufzai and Siddiqi, 1977a,b,c; Lupien et_ al^., 1979), 
the exact mode of action by which it lowers serum lipid levels is 
still unclear. To gain further insight into the action of HMG, studies 
are being carried out to investigate the molecular mechanism of the 
hypolipidemic action of HMG. 
/7-
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The present work involves the study of the effect of HMG on 
serum lipids, lipoproteins and the activity of lipase in hyperlipide-
mic rats. As shown in Table I, HMG significantly reduced serum total 
lipids (20%) in hyperlipidemic rats. Among different lipid fractions, 
there was a significant reduction in serum total and ester cholesterol 
(17.2% and 20.6%, respectively) as well as in triglycerides (29.8%). 
However, serum free cholesterol and phospholipids were not signifi-
cantly reduced. These observations confirm the earlier findings that 
HMG has antihyperlipidemic effect. 
The hypolipidemic action of a compound may involve its interfe-
rence with lipoprotein synthesis or release or impaired lipid absorp-
tion (Sirtori et al., 1975). Since the defective lipoprotein metabo-
lism or lipid transport could be a possible cause of hyperlipidemia or 
several kinds of hyperlipoproteinemias, the most logical mechanism of 
action of a hypolipidemic compound could be its interference with 
lipoprotein metabolism (Kritchevsky, 1975). 
In induced hyperlipidemia, HMG caused a significant decrease in 
total VLDL+LDL lipids (28%) as shown in Table II. All lipid components 
of VLDL+LDL fraction were also reduced remarkably, indicating an over-
all lowering of these lipoproteins. This suggested that HMG interferes 
with lipoprotein metabolism.lt was significant to note that HMG incre-
ased total cholesterol as well as ester cholesterol in HDL fraction but 
free cholesterol was reduced significantly (27.3%).It may be suggested 
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TABLE I. EFFECT OF HMG ON SERUM LIPIDS OF RATS FED FAT-RICH CHOLESTEROL DIET 
(Values are Mean mg/100 ml serum ± standard error for 8 rats in each 
group). 
Cholesterol 
Group Total Triglyce- Phospho-
Lipids Total Free Ester rides lipids 
Control Group 1114 +_ 33 274 ± 10 65 ± 4 208 + 7 265 + 13 319 + 11 
Treated Group 891 +.24 227 +. 8 62 + 1 165 + 8 186 ± 13 268 + 12 
Percent Reduction 20* 17.2* 4.6* 20.6* 29.8* 16 
* All values are significant at 95% confidence limit using Mann-Whitney U-Test 
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TABLE II. EFFECT OF HMG ON LIPOPROTEIN LIPIDS OF RATS FED FAT-RICH CHOLESTEROL 
DIET (Values are Mean mg/100 ml serum ± stadard error for 8 rats in 
each group). 
Total Cholesterol Triglyce- Phospho-
Lipids rides lipids 
Total Free Ester 
A. VLDL + LDL 
Control 617 + 30 178 + 10 34 ± 2 144 ± 9 226 +9 126+3 
Treated 440 + 39 130 + 3 22+3 108 ± 2 156 + 10 101 + 6 
Percent Reduction 28.7* 26.9* 35.3* 25* 31* 19.8* 
B. HDL 
Control 492 + 17 91 ± 6 11 i 1 80 i 6 37 + 5 196 i 9 
Treated 448 ± 12 100 + 7 8 + 1 92+6 30+2 166+9 
Percent Reduction 8.2 +9.9 27.3* +15 18.2 15.3 
* All values are significant at 95% confidence limit using Mann-Whitney 
U-Test. 
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that following HMG treatment/ rate of esterification of free choles-
terol is increased and more free cholesterol, released after 
VLDL+LDL hydrolysis, enters HDL as esterified cholesterol by the 
action of LCAT enzyme. Among several possible mechanisms of action of 
HMG, it has been emphasized that hypolipidemic response of HMG could 
involve a shift in lipoprotein spectrum (Lupien et al., 1973; Yusufi 
and Siddiqi, 1974; Yousufzai and Siddiqi, 1977). HMG has also been 
shown to lower serum LDL and VLDL levels in hyperlipidemic rats 
(Yousufzai and Siddiqi, 1976). On the basis of the observation that 
HMG treatment of rats caused a decrease in serum lipids without any 
increase in the liver lipids, Yousufzai et^  aJ^ . (1976) ruled out 
the possibility of HMG inhibiting the release of VLDL and LDL. 
Our results clearly indicate (Table II) that the most pronoun-
ced lowering effect of HMG was observed on triglycerides of VLDL+LDL 
fraction (31%). It may be suggested that HMG exerts a stimulatory 
effect on the catabolism of main TG carrying lipoproteins by enhancing 
the activity of lipoprotein lipase. The marked decrease in VLDL+LDL 
lipids is found to be associated with an increase in esterified 
cholesterol of HDL as shown in Table II. Since the concentration of 
HDL is related to the catabolism of TG-rich lipoproteins, eleva-
ted HDL-cholesterol levels may be related with the enhanced 
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frational catabolic rate of VLDL and an increased total turn over rate 
of VLDL-TG. It is, therefore, likely that HMG increases the catabolic 
rate of VLDL and total turn over rate of triglycerides. 
The metabolism of VLDL is initiated by lipoprotein lipase cata-
lyzed hydrolysis of its triglycerides. This process involves many 
phases of delipidation and deproteination. There is a clear metabolic 
relation among different lipoprotein particles. Partially degraded 
VLDL particles are converted to IDL. In rats most of the IDL is remo-
ved from the circulation and finally it is metabolized to form LDL. 
Eisenberg et al. (1975) suggested that this pathway involves, prima-
rily, the hepatic lipase anc3 occurs in liver. LDL, HDL and possibly 
IDL are, therefore, the lipoprotein forms which are cleared from the 
circulation by tissue cells. 
The dramatic increase in the hepatic lipase activity (156%) in 
HMG treated animals (Table IV), therefore, supports the above proposi-
tion that HMG increases the FCR of VLDL and total turn over rate of 
triglycerides. These observations on HMG are consistent with the 
effect of Clofibrate, Tiadenol (Sirtori £t £l., 1983) and Bezafibrate 
(Kohlmeier et al., 1986) on lipoproteins. 
A major fraction of plasma HDL is thought to be derived from 
surface remnants of TG rich lipoproteins (Tall and Small, 1978; Green 
£ t ^ . , 1979; Tall^£l., 1982). A smaller fraction is likely to be 
synthesized de novo and secreted from intestine and liver as nascent 
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TABLE III. EFFECT OF HMG ON THE INDICATORS OF ATHEROGENIC RISK IN 
RATS FED FAT-RICH CHOLESTEROL DIET. 
Group 
Control 
Treated 
Percent Reduction 
Total cholesterol 
HDL-cholesterol 
3.0+0.22 
2.27 i OH 
24.33* 
VLDL+LDL-cholesterol 
HDL-cholesterol 
1.96+0.14 
1.30±0.13 
33.67* 
* Values are significant at 95% confidence limit using Mann-Whitney 
U-Test. 
Enzyme 
l^l^ 
TABLE IV. EFFECT OF HMG ON THE ACTIVITY OF LIPASES IN RATS FED FAT-
RICH CHOLESTEROL DIET (Enzyme activity as mean/j moles FFA/ 
mg/h ± standard error for 5 rats in each group). 
Control Treated Percent change 
Myocardial Lipase 0.84 ± .08 0.46 ± .07 
Hepatic Lipase 0.78 + 0.17 2.0 + 0.3 
-45.2* 
+156.4* 
* Values are significant at 95% confidence limit using Mann-Whitney 
U-Test. 
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HDL particles (Glickman and Green,-1977). It has been suggested that 
with the formation of new cholesteryl ester, from phospholipid and 
unesterified cholesterol, catalyzed by the activity of LCAT plus the 
addition of surface components from lipolyzed lipoproein nascent HDL 
particles are converted to larger plasma HDL particles (Hamilton, 
1978 and Eisenberg 1980) which are relatively rich in cholesteryl 
ester (Schaefer and Levy, 1979). A reduced activity of LCAT enzyme 
might, therefore,inhibit reverse cholesterol transport process carried 
out by HDL. An elevated ratio of total cholesterol to HDL-cholesterol 
is also considered to be a better indicator of disturbances in the 
cholesterol ester metabolis<n than the individual values, and might 
contribute to the development of coronary atheromatosis (Wallantin and 
Moberg,1982;Jackson and Lee 1984). The ratio of (VLDL+LDL)-cholesterol 
to HDL-cholesterol has also been reported to be an indicator of IHD 
risk (Miller et al., 1982). From the results it is clear that, like 
Cholestyramine (Jones et al., 1984) and Bezafibrate (Gavish et al., 
1986), HMG is effective in reducing these indicators of atherogenic 
risk (Table III). Although we have not measured the activity of 
LCAT enzyme, it is quite likely that HMG would bring about an increase 
in the activity of this enzyme. 
The effect of HMG administration on the activities of hepatic 
and myocardial lipase is shown in Table IV. HMG exhibited stimulating 
effect on the activity of hepatic lipase, whereas activity of myocar-
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dial lipase was found to be decreased on HMG treatment. These two 
enzymes differ in their metabolic functions. Myocardial lipase is a 
kind of lipoprotein lipase localized on the capillary wall of the 
endothelial cells of rat heart (Twu ft^  aJ^ -' 1975). Rat heart lipase 
has been reported to hydrolyze diglyceride monolayers as well as 
triglyceride monolayers (Chung and Scanu/ 1977) and monoglyceride in 
miceller or albumin bound substrates (Twu et^ al.,1976). The physiolo-
gical role of this lipase lies in the assimilation of TG fatty acids 
into the tissue. The contact between enzyme and circulating TG at the 
capillary wall results into the rapid production of fatty acids, part 
of which may escape into fhe circulation (Smith and Scow, 1979). Most 
of the fatty acids , however, are transported through the endothelial 
layer and assimilated into tissue cells for oxidation or re-esterific-
ation to storage triglycerides (Nilsson-Ehle et al.,1980). It may be 
suggested that HMG treatment might therefore results in the decreased 
assimilation of lipids into the heart through the endothelial cells. 
Hepatic lipase has been suggested as the enzyme most active on 
HDL (Musliner et al.., 1979; Kuusi et al^ ., 1980; Landin et aJ^ ., 1984). 
It has also been reported to play a role in the catabolism of HDL pho-
spholipids (Jansen et^  al^ ., 1980; Murase and Itakura, 1981). In vitro 
studies have also confirmed the role of hapatic lipase in the hydroly-
sis of HDL-phospholipids and triglycerides in liver (Musliner et al., 
1979; Shirai £it aJ^ ., 1981) and the subfraction HDL appears to be the 
- ^7 -
preferred substrate (Groot et_ aJ^ . ,1981) .The removal of cholesterol and 
phospholipid components from LDL and HDL particles during their passa-
ge through the liver tias~also been attributed to the activity of hepa-
tic lipase (Sauar and Stokke, 1979; Kuusi £t aJ^ . / 1979). The increase 
in hepatic lipase activity by HMG treatment may suggest an increased 
removal of lipoprotein lipids through the liver. Furthermore, it 
indicates that somehow, HMG may help in HDL mediated reverse choles-
terol transport from peripheral tissues to the liver where it is 
finally catabolized and excreted out. 
- ^ 8 
FUTURE PLAN 
Further studies on the molecular mechanism of hypolipidemic 
action of HMG will involve the following approach-
1. In order to find out the effect of HMG administration on the 
plasma levels of lipoproteins/ quantitation of different lipopro-
teins will be made in normal and hyperlipidemic rats after HMG 
treatment. 
2. The compositional changes in the plasma lipoproteins shall be 
studied in HMG treated- rats. 
3. To understand the effect of HMG on the metabolism of lipoproteins, 
the activities of hapatic lipase and lipoprotein lipase in post-
heparin plasma will be measured in HMG treated hypercholestero-
lemic and hypertriglyceridemic rats. 
4. Plasma lecithin cholesterol acyl transferase (LCAT) activity will 
be measured in normal and hypercholesterolemic rats after HMG 
treatment to elucidate the involvement of HMG with the esterifi-
cation of plasma cholesterol and its transport by high density 
lipoprotein. 
5. Studies on the effect of HMG on platelet aggregation and disaggre-
gation will be made using normal and hyperlipidemic rats. 
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